Avacta Group (AVCT) RNS Announcements

Add to Alert list
Date Time Source Announcement
02 May 2017 07:00 AM
RNS
Avacta to Present at BioTrinity 2017
24 Apr 2017 07:00 AM
RNS
Diagnostics firm take rights to several Affimers
19 Apr 2017 07:00 AM
RNS
Avacta to Present at the Shares Spotlight Evening
12 Apr 2017 07:15 AM
RNS
Hardman Research: Another important box ticked
06 Apr 2017 02:23 PM
RNS
Holding(s) in Company
06 Apr 2017 02:23 PM
RNS
Holding(s) in Company
06 Apr 2017 10:22 AM
RNS
Director/PDMR Shareholding
03 Apr 2017 07:00 AM
RNS
Results of Immunogenicity Study with Human Samples
03 Apr 2017 07:00 AM
RNS
Interim Results for the Period Ended 31 Jan 2017
31 Mar 2017 09:31 AM
RNS
Avacta Presents at Investor Evening Hosted by TPI
31 Mar 2017 07:00 AM
RNS
London Growth and Innovation Forum Presentation
22 Mar 2017 09:00 AM
RNS
Avacta to present at the UK Investor Show
21 Mar 2017 07:15 AM
RNS
Hardman Research: Low response would be positive!
30 Jan 2017 07:00 AM
RNS
Director/PDMR Shareholding
20 Jan 2017 11:35 AM
RNS
Result of Annual General Meeting
20 Jan 2017 07:00 AM
RNS
Trading Update
11 Jan 2017 07:00 AM
RNS
Presenting at London Growth and Innovation Forum
05 Jan 2017 07:00 AM
RNS
Director Dealing and Issue of Equity
20 Dec 2016 07:00 AM
RNS
Director/PDMR Shareholding
16 Dec 2016 05:14 PM
RNS
Holding(s) in Company
01 Dec 2016 07:00 AM
RNS
Notice of AGM, Accounts and Directorate Change
23 Nov 2016 07:00 AM
RNS
Technical Update: Affinity Separation
07 Nov 2016 07:00 AM
RNS
Cancer Expert joins Scientific Advisory Board
02 Nov 2016 07:00 AM
RNS
CAR-T Cell Therapy Research Collaboration in US
01 Nov 2016 07:00 AM
RNS
Results from first Affimer pre-clinical studies
21 Oct 2016 11:39 AM
RNS
Director's Dealing
17 Oct 2016 01:00 PM
RNS
Hardman Research: Great strides to strategic goals
17 Oct 2016 07:00 AM
RNS
Prelim Results for the Year Ended 31 July 2016
04 Oct 2016 03:28 PM
RNS
Issue of Equity
26 Sep 2016 11:21 AM
RNS
Notice of Results
22 Sep 2016 07:00 AM
RNS
Positive results from first preclinical studies
12 Sep 2016 07:00 AM
RNS
Change of Adviser
31 Aug 2016 02:17 PM
RNS
Change of Registered Office
16 Aug 2016 07:00 AM
RNS
New Facilities in Cambridge and Wetherby
10 Aug 2016 07:00 AM
RNS
Grant Funding
03 Aug 2016 07:00 AM
RNS
Key Affimer patents to be granted in Europe and US
01 Aug 2016 07:00 AM
RNS
Trading Statement
19 Jul 2016 03:13 PM
RNS
Holding(s) in Company
19 Jul 2016 07:15 AM
RNS
Hardman report: New Affimer opportunities
14 Jul 2016 07:00 AM
RNS
Collaboration with Glythera
08 Jul 2016 07:00 AM
RNS
Director/PDMR Shareholding
22 Jun 2016 07:00 AM
RNS
Affimer Binders for Zika Virus Diagnostics
16 Jun 2016 11:08 AM
RNS
Issue of Equity
13 Jun 2016 07:00 AM
RNS
Collaboration with Mologic
29 Apr 2016 03:04 PM
RNS
Director's Dealing
25 Apr 2016 07:00 AM
RNS
Half-year Report
19 Apr 2016 07:00 AM
RNS
Affimer Therapeutic Platform Development Milestone
07 Apr 2016 07:00 AM
RNS
Director's Dealing
05 Apr 2016 07:00 AM
RNS
Investor Evening
15 Mar 2016 07:00 AM
RNS
Issue of Equity

Avacta Group plc is a United Kingdom-based life sciences company focused on improving healthcare outcomes through targeted cancer treatments and diagnostics. The Company has two segments: Therapeutics and Diagnostics. The Therapeutics segment is a clinical stage oncology biotech division harnessing therapeutic platforms to develop novel, highly targeted cancer drugs. The Diagnostics segment is focused on supporting healthcare professionals and broadening access to diagnostics.

It has two platforms: preICISION and Affimer. The Company's preICISION platform is a highly specific substrate for fibroblast activation protein (FAP) which is upregulated in most solid tumors compared with healthy tissues. The preICISION platform harnesses this tumor specific protease to activate preICISION peptide drug conjugates and preICISION antibody/Affimer drug conjugates in the tumor microenvironment. Its lead preICISION program AVA6000, a peptide drug conjugate form of doxorubicin, is in Phase 1 studies.

Avacta Group share price launched at 5,448p in 2003. 

UK 100

Latest directors dealings